Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Better Buy: Gilead Sciences vs. Pfizer

TheMotleyFool

0 0

Better Buy: Gilead Sciences vs. PfizerPhoto, wide shot, wide-angle lens, Clinical research organization, Blue hour, twilight, cool, ISO1200, slow shutter speed, photo by Michael Light: https://img.theapi.app/temp/c28f6640-54ba-4d2b-afbe-b5fd3b0ee19e.png

Gilead Sciences (NASDAQ: GILD) and Pfizer (NYSE: PFE) are two of the most competent pharmaceutical companies in the industry. Both have impressively broad and advanced drug development pipelines, and both have a history of profitable operations, not to mention acceptable dividend yields above 3%.

Either stock could be a good anchor for a pharma portfolio. If there's only room for one, examining the details of each company's performance in the last five years will be helpful to decide which warrants a buy.

Image source: Getty Images.

Source Fool.com

Like: 0

PFE

Share